Related Experiment Video
Updated: May 3, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Severe clinical outcome is uncommon in Clostridium difficile infection in children: a retrospective cohort study
Kevin L Schwartz1, Ilyse Darwish, Susan E Richardson
1Division of Infectious Diseases, The Hospital for Sick Children, University of Toronto, 555 University Ave, Rm 7306, Toronto, ON M5G 1X8, Canada. Kevin.schwartz@sickkids.ca.
Insights
Severe outcomes from Clostridium difficile infection (CDI) are rare in children, with most cases resolving within 30 days. Further research is needed to understand risk factors and treatment for pediatric CDI.
Area of Science:
- Pediatric Infectious Diseases
- Gastroenterology
- Epidemiology
Background:
- Clostridium difficile infection (CDI) is a leading cause of healthcare-associated diarrhea in children and adults.
- While severe CDI complications are rising in adults, this trend is not established in pediatric populations.
- This study investigates pediatric CDI features, focusing on severe outcomes.
Purpose of the Study:
- To examine the clinical features of Clostridium difficile infection (CDI) in children.
- To determine the incidence of severe outcomes in pediatric CDI cases.
- To identify potential risk factors and strain characteristics associated with pediatric CDI.
Main Methods:
- Retrospective chart review of pediatric patients diagnosed with CDI via cytotoxin assay (August 2008-July 2012).
- Data collection included demographics, acquisition source, clinical/laboratory findings, treatment, and outcomes.
- Isolates underwent pulsed-field gel electrophoresis and toxin gene analysis (tcdA, tcdB, cdtB, tcdC).
Main Results:
- Ninety percent of pediatric CDI cases resolved within 30 days; only 2% experienced severe outcomes.
- No colectomies were performed, and only one death was linked to CDI.
- Nosocomial acquisition accounted for 74% of cases. NAP4 was the most frequent strain (24%), associated with higher relapse rates but not severe outcomes.
Conclusions:
- Severe outcomes from Clostridium difficile infection (CDI) are infrequent in children compared to adults.
- Prospective studies are needed to elucidate pediatric CDI risk factors, optimal treatments, and the role of specific strains like NAP4.
Background:
Clostridium difficile infection (CDI) is the most common cause of health care-associated diarrhea in children and adults. Although serious complications of CDI have been reported to be increasing in adults, this trend has not yet been demonstrated in children. The purpose of this study was to examine the features of CDI in a pediatric population, with special attention to the occurrence of CDI-related severe outcomes.
Methods:
A chart review was conducted for patients with C. difficile infection detected by cytotoxin assay between August, 2008 and July, 2012. Basic demographics, mode of acquisition (nosocomial versus community), laboratory and clinical features, treatment, and outcome data were collected. Pulsed-field gel electrophoresis and polymerase chain reaction detection of toxin A (tcdA), toxin B (tcdB), binary toxin (cdtB) and tcdC genes were performed on isolates from nosocomial cases by the National Microbiology Laboratory, Winnipeg, Manitoba.
Results:
Ninety percent of children with CDI experienced resolution of symptoms by 30 days after disease onset and 2% experienced a severe outcome. There were no cases where colectomy was performed for CDI, and only one case where CDI contributed to death. Various combinations of clinical and laboratory features were not predictive of a severe outcome. Seventy-four percent of cases were nosocomial-associated. Among all cultured strains, the NAP4 strain occurred most frequently (24%), followed by NAP1 (11%). There was no association between strain type and clinical outcome; however, relapses were significantly more frequent in NAP4-infected children.
Conclusions:
Severe outcomes due to CDI are uncommon in children compared to adults. Further prospective pediatric studies on CDI in community and hospital settings are required to better understand risk factors, optimal treatment and the significance of NAP4 in pediatric CDI.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Clinical Significance of Antibiotic Resistance
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Dosing: Infants and Children
Inflammatory Bowel Disease IV: Clinical Manifestations

